Companies / India
Dr. Reddy's Reports Profit Boost
October 2006 | Company Finance AlertIndian drugmaker Dr. Reddy's has reported that profit in the third quarter surged by as much as 300% to INR2.8bn (US$62mn), mainly due to deals with Merck & Co on so-called 'authorised generic' formulations of Zocor (simvastatin) and Proscar (finasteride). However, the firm noted that 180-day Hatch-Waxman exclusivity will expire in December
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
